Trial reportBMC pediatrics2026
Eficacy and safety of restricted fluid therapy in transient tachypnea of the newborn: a randomized controlled study.
Trial report in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07549945 (Eficacy and Safety of Restricted Fluid Therapy in Transient Tachypnea of the Newborn), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Eficacy and Safety of Restricted Fluid Therapy in Transient Tachypnea of the Newborn: A Randomized Controlled Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence suggests that increased intravascular and interstitial fluid load in neonates with transient tachypnea of the newborn (TTN) may delay the clearance of fetal alveolar fluid (FAF). Restricted fluid (RF) therapy may accelerated FAF clearance and improve outcomes in these infants.
methodsTerm and late preterm infants with TTN requiring nasal intermittent positive pressure ventilation (NIPPV) were randomized within first 2 h after birth to receive either RF or standard fluid (SF) therapy. Primary outcomes were the duration of NIPPV and the day of discharge. Secondary outcomes included changes in weight, urine output, biochemical parameters, and monitoring of potential adverse effects.
resultsForty-four infants were analyzed. NIPPV duration (36 ± 25 vs. 57 ± 23 h; p = 0.012) and the time to full enteral feeding (65 ± 25 vs. 94 ± 20 h; p < 0.005) were shorter in the RF group. Although the day of discharge was earlier in the RF group, the difference did not reach statistical significance (6.5 ± 1.3 vs. 7.5 ± 2.3 days; p = 0.084). Mean weight loss on postnatal day 5 was higher in the RF group (p < 0.005). No significant differences were observed in urine output, serum electrolytes, or renal function tests. Hypernatremia (ranging from 146 to 150 mmol/L) developed in seven patients (four in the SF group and three in the RF group), and no hypoglycemia or serious adverse events occurred.
conclusionRestricted fluid therapy appears safe and effective in TTN infants requiring NIPPV, reducing respiratory support duration and enabling earlier full enteral feeding.
trial registrationClinicalTrials.gov, NCT07549945. Registered 23 April 2026, retrospectively registered. The study was conducted between October 2021 and July 2023. During the final stages of the study, the devastating earthquakes that struck southeastern Türkiye in February 2023 caused major disruptions to clinical and academic activities at our institution, contributing to delays in manuscript preparation and trial registration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.